ES2233479T3 - Derivados de triazaespiro (5,5) undecano y composiciones farmaceuticas que los comprenden, como ingrediente activo. - Google Patents

Derivados de triazaespiro (5,5) undecano y composiciones farmaceuticas que los comprenden, como ingrediente activo.

Info

Publication number
ES2233479T3
ES2233479T3 ES00979050T ES00979050T ES2233479T3 ES 2233479 T3 ES2233479 T3 ES 2233479T3 ES 00979050 T ES00979050 T ES 00979050T ES 00979050 T ES00979050 T ES 00979050T ES 2233479 T3 ES2233479 T3 ES 2233479T3
Authority
ES
Spain
Prior art keywords
alkylene
alkyl
cyc
alkenyl
undecano
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00979050T
Other languages
English (en)
Inventor
Hiromu c/o Minase Research Institute HABASHITA
Shin-ichi c/o Minase Research Institute HAMANO
Shiro c/o Minase Research Institute SHIBAYAMA
Yoshikazu c/o Minase Research Institute TAKAOKA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ono Pharmaceutical Co Ltd
Original Assignee
Ono Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co Ltd filed Critical Ono Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2233479T3 publication Critical patent/ES2233479T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Un derivado de triazaespiro[5, 5]undecano de fórmula (I) **(Fórmula)** [donde R1 es (1) hidrógeno, (2) alquilo C1-C18, (3) alquenilo C2-C18, (4) alquinilo C2-C18, (5) -COR6, (6) -CONR7R8, (7) -COOR9, (8) -SO2R10, 35 (9) -COCOOR11, (10) -CONR12COR13, (11) Cyc 1, o (I) (12) alquilo C1-C18, alquenilo C2-C18 o alquinilo sustituido con 1-5 de los seleccionados opcionalmente entre (a) halógeno, (b) -CONR7R8, (c) -COOR9, (d) -OR14, (e) -SR15, (f) -NR16R17, (g) -NR18COR19, (h) -SO2NR20R21, (i) -OCOR22, (j) -NR23SO2R24, (k) -NR25COOR26, (l) -NR27CONR28R29, (m) Cyc 1, (n) ceto o (o) -N(SO2R24)2, (donde R6-R9, R11-R21, R23, R25 y R27-R29 son cada uno independientemente, (1) hidrógeno, (2) alquilo C1-C18, (3) alquenilo C2-C18, (4) alquinilo C2-C18, (5) Cyc 1, o (6) alquilo C1-C18, alquenilo C2-C18 o alquinilo C2-C18 sustituido con 1-5 de los seleccionados opcionalmente entre (a) Cyc 1, (b) halógeno, (c) -OR30, (d) -SR31, (e) -NR32R33, (f) -COOR34, (g) -CONR35R36, (h) -NR37COR38, (i) -NR39SO2R40 o (j) -N(SO2R40)2, o R7 y R8, R20yR21, R28 y R29, tomados juntos, son 1) alquileno C2-C6, 2) -(alquileno C2-C6)-O-(alquileno C2-C6)-, 3) -(alquileno C2-C6)-S-(alquileno C2-C6)- o 4) -(alquileno C2-C6)-NR195-(alquileno C2-C6)-, (donde R195 es hidrógeno, alquilo C1-C8, fenilo o alquilo C2-C8 sustituido con fenilo).
ES00979050T 1999-12-03 2000-12-01 Derivados de triazaespiro (5,5) undecano y composiciones farmaceuticas que los comprenden, como ingrediente activo. Expired - Lifetime ES2233479T3 (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
JP34496799 1999-12-03
JP34496799 1999-12-03
JP2000018673 2000-01-27
JP2000018673 2000-01-27
JP2000027968 2000-02-04
JP2000027968 2000-02-04
JP2000147882 2000-05-19
JP2000147882 2000-05-19

Publications (1)

Publication Number Publication Date
ES2233479T3 true ES2233479T3 (es) 2005-06-16

Family

ID=27480653

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00979050T Expired - Lifetime ES2233479T3 (es) 1999-12-03 2000-12-01 Derivados de triazaespiro (5,5) undecano y composiciones farmaceuticas que los comprenden, como ingrediente activo.

Country Status (18)

Country Link
US (1) US7119091B2 (es)
EP (1) EP1236726B1 (es)
JP (1) JP4721087B2 (es)
KR (1) KR100613176B1 (es)
CN (1) CN1246321C (es)
AT (1) ATE283854T1 (es)
AU (1) AU780419C (es)
BR (1) BR0016111A (es)
CA (1) CA2394679A1 (es)
DE (1) DE60016454T2 (es)
ES (1) ES2233479T3 (es)
HU (1) HUP0300641A2 (es)
MX (1) MXPA02005465A (es)
NO (1) NO323631B1 (es)
NZ (1) NZ519183A (es)
PT (1) PT1236726E (es)
TW (1) TWI224597B (es)
WO (1) WO2001040227A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20032531A3 (cs) * 2001-03-19 2004-01-14 Ono Pharmaceutical Co., Ltd. Derivát triazaspiro[5.5]undekanu a farmaceutická kompozice obsahující tento derivát jako účinnou složku
EP1378509A4 (en) 2001-03-19 2009-03-25 Ono Pharmaceutical Co DRUGS WITH TRIAZASPIRO ç5.5] UNDECANDERIVATES AS ACTIVE SUBSTANCE
CZ2004500A3 (cs) * 2001-10-23 2005-03-16 Ono Pharmaceutical Co., Ltd. Léčivo osahující kombinaci triazaspiro[5.5] undekanového derivátu s inhibitorem isozymu 3A4 cytochromu P450 a/nebo inhibitorem P-glykoproteinu
AU2003211427A1 (en) * 2002-02-18 2003-09-04 Ishihara Sangyo Kaisha, Ltd. Pyridine derivatives or salts thereof and cytokine production inhibitors containing the same
US7064211B2 (en) * 2002-03-22 2006-06-20 Eisai Co., Ltd. Hemiasterlin derivatives and uses thereof
CA2497903A1 (en) * 2002-09-18 2004-04-01 Ono Pharmaceutical Co., Ltd. Triazaspiro[5.5]undecane derivatives and drugs comprising the same as the active ingredient
US7361758B2 (en) 2002-09-18 2008-04-22 Ono Pharmaceutical Co., Ltd. Crystals of triazaspiro[5.5]undecane derivative
EP1571146A4 (en) * 2002-12-10 2010-09-01 Ono Pharmaceutical Co NITROGENIC HETEROCYCLIC COMPOUNDS AND THEIR MEDICAL USE
WO2004054581A2 (en) * 2002-12-13 2004-07-01 Smithkline Beecham Corporation Cyclohexyl compounds as ccr5 antagonists
EP1570860A4 (en) * 2002-12-13 2009-06-03 Ono Pharmaceutical Co ANTAGONIST AND AGONIST BINDING TO A STRONG BINDING SITE OF THE CHEMOKINE RECEPTOR
RU2366655C2 (ru) * 2003-03-14 2009-09-10 Оно Фармасьютикал Ко., Лтд. Азотсодержащие гетероциклические производные и лекарственные средства, содержащие их в качестве активного ингредиента
WO2004092169A1 (ja) 2003-04-18 2004-10-28 Ono Pharmaceutical Co., Ltd. スピロピペリジン化合物およびその医薬用途
EP1621540A4 (en) * 2003-04-21 2008-07-23 Ono Pharmaceutical Co HETEROCYCLIC COMPOUNDS CONTAINING NITROGEN AND USE THEREOF
RU2006132465A (ru) 2004-02-10 2008-03-20 Ф.Хоффманн-Ля Рош Аг (Ch) Модуляторы хемокинового рецептора ccr5
ATE382623T1 (de) * 2004-06-09 2008-01-15 Hoffmann La Roche Octahydropyrrolo(3,4-c)pyrrolderivate und deren verwendung als antivirale mitteln
CA2584502A1 (en) * 2004-06-24 2006-01-05 Incyte Corporation 2-methylpropanamides and their use as pharmaceuticals
US8071624B2 (en) 2004-06-24 2011-12-06 Incyte Corporation N-substituted piperidines and their use as pharmaceuticals
WO2006002350A1 (en) * 2004-06-24 2006-01-05 Incyte Corporation Amido compounds and their use as pharmaceuticals
CA2571258A1 (en) * 2004-06-24 2006-01-05 Incyte Corporation Amido compounds and their use as pharmaceuticals
AU2005273986A1 (en) * 2004-08-10 2006-02-23 Incyte Corporation Amido compounds and their use as pharmaceuticals
US8143404B2 (en) 2004-09-13 2012-03-27 Ono Pharmaceutical Co., Ltd Nitrogenous heterocylic derivative and medicine containing the same as an active ingredient
US8110581B2 (en) * 2004-11-10 2012-02-07 Incyte Corporation Lactam compounds and their use as pharmaceuticals
EP1819333A1 (en) * 2004-12-01 2007-08-22 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and gw873140
US20060235028A1 (en) * 2005-04-14 2006-10-19 Li James J Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
EP1889622A4 (en) * 2005-05-31 2009-12-23 Ono Pharmaceutical Co SPIROPIPERIDINE COMPOUND AND MEDICINAL USE THEREOF
CA2644368A1 (en) 2006-03-10 2007-09-20 Ono Pharmaceutical Co., Ltd. Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
AU2007275301A1 (en) * 2006-07-20 2008-01-24 Amgen Inc. Substituted azole aromatic heterocycles as inhibitors of 11-beta-HSD-1
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
GB0625523D0 (en) * 2006-12-21 2007-01-31 Ge Healthcare Ltd In vivo imaging agents
WO2008119663A1 (en) 2007-03-29 2008-10-09 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
CL2008001839A1 (es) * 2007-06-21 2009-01-16 Incyte Holdings Corp Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
US7977358B2 (en) * 2007-07-26 2011-07-12 Hoffmann-La Roche Inc. Pyrazol derivatives
CA2721060A1 (en) * 2008-04-09 2009-10-15 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
WO2010118159A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
WO2010118155A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
IN2012DN00352A (es) * 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
RU2015143910A (ru) 2010-02-03 2018-12-28 Инфинити Фармасьютикалз, Инк. Ингибиторы амид-гидролазы жирных кислот
US10383894B2 (en) * 2010-03-17 2019-08-20 Lutran Industries, Inc. Human medicinal treatment using salt of peroxymonosulfuric acid
MY170236A (en) 2010-10-06 2019-07-11 Glaxosmithkline Llc Benzimidazole derivatives as pi3 kinase inhibitors
US10092574B2 (en) 2012-09-26 2018-10-09 Valorisation-Recherche, Limited Partnership Inhibitors of polynucleotide repeat-associated RNA foci and uses thereof
WO2014093816A2 (en) 2012-12-13 2014-06-19 Daniel Scott Marshall Magnetically polarized photonic device
US11084807B2 (en) 2016-08-18 2021-08-10 Vidac Pharama Ltd. Piperazine derivatives, pharmaceutical compositions and methods of use thereof
CN108727400B (zh) * 2017-05-24 2021-07-09 四川晶华生物科技有限公司 一种治疗肿瘤的化合物
CN107216335B (zh) * 2017-06-29 2019-04-30 上海药明康德新药开发有限公司 一种叔丁基1-(羟甲基)-3-氧杂-9-氮杂螺[5.5]十一烷-9-甲酸基酯制法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS231227B1 (en) * 1982-10-01 1984-10-15 Evzen Kasafirek 2,5-pierazindion derivatives
CS260899B1 (en) * 1986-11-07 1989-01-12 Evzen Kasafirek Remedy for gastrointestinal diseases
WO1993013101A1 (fr) * 1991-12-27 1993-07-08 Yoshitomi Pharmaceutical Industries, Ltd. Compose de pyridonecarboxylate, son utilisation pharmaceutique et compose spiro
WO1997011940A1 (en) 1995-09-29 1997-04-03 Eli Lilly And Company Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation
WO1998025605A1 (en) 1996-12-13 1998-06-18 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
US6288083B1 (en) * 1998-09-04 2001-09-11 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor

Also Published As

Publication number Publication date
DE60016454T2 (de) 2005-08-04
CN1433419A (zh) 2003-07-30
US7119091B2 (en) 2006-10-10
NO323631B1 (no) 2007-06-18
ATE283854T1 (de) 2004-12-15
CA2394679A1 (en) 2001-06-07
EP1236726A1 (en) 2002-09-04
DE60016454D1 (de) 2005-01-05
MXPA02005465A (es) 2003-10-15
KR20030003218A (ko) 2003-01-09
TWI224597B (en) 2004-12-01
NZ519183A (en) 2005-02-25
BR0016111A (pt) 2003-03-25
JP4721087B2 (ja) 2011-07-13
HUP0300641A2 (hu) 2003-06-28
KR100613176B1 (ko) 2006-08-17
AU1650601A (en) 2001-06-12
CN1246321C (zh) 2006-03-22
NO20022609D0 (no) 2002-05-31
AU780419C (en) 2005-09-29
US20040097511A1 (en) 2004-05-20
PT1236726E (pt) 2005-04-29
EP1236726A4 (en) 2003-01-15
NO20022609L (no) 2002-07-26
WO2001040227A1 (en) 2001-06-07
AU780419B2 (en) 2005-03-17
EP1236726B1 (en) 2004-12-01

Similar Documents

Publication Publication Date Title
ES2233479T3 (es) Derivados de triazaespiro (5,5) undecano y composiciones farmaceuticas que los comprenden, como ingrediente activo.
SG127738A1 (en) Heterocyclic compounds based on n6-substituted adenine, methods of their preparation, their use for preparation of drugs, pharmaceutical preparations containing these compounds
PA8539801A1 (es) Derivados del ácido isoftálico como inhibidores de metaloproteinasas de la matriz
PA8550101A1 (es) Derivados de benzamida tiazol y composiciones farmacéuticas para inhibir la proliferación de células, y métodos para su utilización
NO20052469L (no) Inhibitorer av II-beta-hydroksysteroid-dehydrogenase type 1 og type 2.
TR200100439T2 (tr) 1H-İmidazopiridin türevleri
BR0313943A (pt) Composto benzanilida substituìdo e agente de controle de organismo nocivo
CY1110232T1 (el) Παραγωγα 2-αρυλ-6-φαινυλ-ιμιδαζο[1,2-α]πυριδιν, η παρασκευη τους και η εφαρμογη τους στη θεραπευτικη αγωγη
PT718293E (pt) Composto ciclodepsipeptidico
CY1106679T1 (el) Αζαδικυκλικες ετεροκυκλικες ενωσεις ως τροποποιητες κανναβινοειδους υποδοχεα
DK1019368T3 (da) Acylsulfamoylbenzoesyreamider, nytteplantebeskyttelsesmidler indeholdende disse samt fremgangsmåder til deres fremstilling
AR060749A1 (es) Uso de bifenilamidas de acido arilcarboxilico para el tratamiento de semillas
MY105402A (en) 17-beta-substituted-4-aza-5alpha-androstan-3-one derivatives and process for their preparation.
BRPI0414593A (pt) derivados de ácido sulfonamida substituìda-indol-2-carboxìlico como inibidores de pai-1
DOP2006000063A (es) Derivados de ciclopropanocarboxamida
NO20021859D0 (no) Nye digosakkarider, deres fremstilling samt farmasöytiske preparater
ATE353641T1 (de) Benzamide als kaliumkanal-inhibitoren
AR015312A1 (es) Compuestos inhibidores no peptidilicos de la union a las celulas dependientes de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunesy respiratorias, composicion farmaceutica y uso de los compuestos en la preparacion de medicamentos
MX9703282A (es) Bencilglicosidos polianionicos como inhibidores de la proliferacion de las celulas del musculo liso.
CY1109808T1 (el) Αρυλινδενο-πυριδινες και αρυλινδενο-πυριμιδινες και η χρηση τους ως ανταγωνιστων των υποδοχεων αδενοσινης α2α
ATE464910T1 (de) Humane cd80-mutante und zusammensetzungen und methoden zu deren herstellung und verwendung
MX2022001678A (es) Derivados amidas hibridas de anfotericina b.
AR024747A1 (es) Derivados de aminotiazoles, su preparacion y las composiciones farmaceuticas que los contienen.
AR031837A1 (es) Derivados amino substituidos ramificados de 3-amino-1-fenil-1h [1, 2, 4] triazol, su utilizacion, procedimientos para su preparacion y composiciones farmaceuticas que los contienen
PE296A1 (es) Derivados de 2-imidazolina-5-onas fungicidas